LCID
Lucid Group, Inc.
LCID offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
TXRH
Texas Roadhouse, Inc.
TXRH has the edge over LCID overall, supported by lower modeled downside.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
TXRH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
TXRH's revenue, profitability, cash flow and balance sheet are all currently healthy.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
TXRH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 25x | $158 | -15% |
| Fair | 28x | $177 | -4.7% |
| Current | 29x | $186 | — |
| Expensive | 34x | $219 | +18% |
Historical ranges are pointers, not guarantees.
TXRH's PE is in its fair range at 29x.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
TXRH Forward outlook
There aren't enough analyst estimates for TXRH to show an outlook.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
TXRH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $6.37 | -2.6% |
| Q2 2026 | $6.26 | -4.4% |
| Q1 2026 | $6.27 | -3.2% |
| Q4 2025 | $6.10 | -5.7% |
| Q3 2025 | $6.54 | +12% |
| Q2 2025 | $6.55 | +19% |
| Q1 2025 | $6.48 | +31% |
| Q4 2024 | $6.47 | +43% |
TXRH has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over TXRH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
TXRH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +9.5% |
| Q2 2026 | $1.7B | +11% |
| Q1 2026 | $1.6B | +13% |
| Q4 2025 | $1.5B | +3.1% |
| Q3 2025 | $1.4B | +13% |
| Q2 2025 | $1.5B | +13% |
| Q1 2025 | $1.4B | +9.6% |
| Q4 2024 | $1.4B | +23% |
TXRH's revenue has grown year over year for 23 quarters in a row: $1.6B last quarter, up 9.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.5% | -0.2 points |
| Q2 2026 | 8.5% | -1.2 points |
| Q1 2026 | 9% | -0.3 points |
| Q4 2025 | 6.5% | -3.1 points |
| Q3 2025 | 6.8% | -1.3 points |
| Q2 2025 | 9.7% | -1 points |
| Q1 2025 | 9.3% | -0.8 points |
| Q4 2024 | 9.6% | +2.5 points |
TXRH has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
TXRH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.1M | -25% |
| Q2 2026 | $81.5M | +128% |
| Q1 2026 | $178.9M | +12% |
| Q4 2025 | $131.3M | +1.2% |
| Q3 2025 | $14.7M | -69% |
| Q2 2025 | $35.7M | -36% |
| Q1 2025 | $160.4M | -3.3% |
| Q4 2024 | $129.7M | +82% |
TXRH has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
TXRH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -135K shares |
| 1 year | -1% | -691K shares |
| 3 years | -1.8% | -1.2M shares |
| 5 years | -6.2% | -4.4M shares |
| Available history | -7.2% | -5.1M shares |
TXRH has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $12.4M |
| Q2 2026 | $43.7M |
| Q1 2026 | $28.2M |
| Q4 2025 | $50M |
| Q3 2025 | $40M |
| Q2 2025 | $10.3M |
| Q1 2025 | $50.2M |
| Q4 2024 | $35.3M |
TXRH spent $134M buying back its own shares over the past year, down 1.1% from the year before.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TXRH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.2x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
TXRH has more cash than debt.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
TXRH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.0 | Neutral |
| Stochastic | 47.9 | Neutral |
TXRH's weekly RSI is 54 (neutral) and its Stochastic is 48 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
TXRH PE vs Consumer Cyclical Sector
| Metric | TXRH | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 18x | 62% above |
| PE % | 58 | 47 | 11 pts above |
TXRH is trading at 29x earnings, a 62% premium to the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
TXRH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $170.5 | 9.1% above |
| 20 week MA | $185.0 | 0.5% above |
| 50 week MA | $178.9 | 4% above |
| 100 week MA | $177.4 | 4.8% above |
| 200 week MA | $156.4 | 19% above |
TXRH has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
TXRH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $55.0 | $80.0 | +45% |
| 2021 | $80.0 | $88.8 | +11% |
| 2022 | $88.8 | $96.3 | +8.5% |
| 2023 | $96.3 | $122.2 | +27% |
| 2024 | $122.2 | $181.9 | +49% |
| 2025 | $181.9 | $170.8 | -6.1% |
| 2026 YTD | $170.8 | $186.0 | +8.9% |
TXRH has the edge over LCID on returns for 2026, with the stronger performance.